Clinical trial · Interventional
Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients
Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients With CpG7909, Tumor Antigenic Peptides and Montanide
NCT00112229CI-TRIAL-00010102completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether vaccination with tumor antigenic peptides and both CpG and Montanide adjuvants can induce an immune response in melanoma patients and to assess the safety of this vaccination.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| group 1 | Biological | — | UNRESOLVED |
| group 2 | Biological | — | UNRESOLVED |
| group 3 | Biological | — | UNRESOLVED |
| group 4 | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- group 1
- description
- Melan-A analog peptide + CpG + Montanide
- interventionNames
- Biological: group 1
- type
- EXPERIMENTAL
- label
- group 2
- description
- Melan-A natural peptide + CpG + Montanide
- interventionNames
- Biological: group 2
- type
- EXPERIMENTAL
- label
- group 3
- description
- Melan-A natural peptide + Tyrosinase YMD peptide + CpG + Montanide
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed stage III or stage IV melanoma * Tumor expression of Melan-A +/- Tyrosinase * Human leukocyte antigen-A2 (HLA-A2) positive Exclusion Criteria: * Clinically significant heart disease * Serious illnesses, eg, serious infections requiring antibiotics, bleeding disorders or uncontrolled peptic ulcer, or seizure or central nervous system disorders * History of immunodeficiency disease or autoimmune disease * Coagulation or bleeding disorders
References
Publications (2)
- RESULTSpeiser DE, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC, Romero P. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005 Mar;115(3):739-46. doi: 10.1172/JCI23373. PMID 15696196
- RESULTBaumgaertner P, Jandus C, Rivals JP, Derre L, Lovgren T, Baitsch L, Guillaume P, Luescher IF, Berthod G, Matter M, Rufer N, Michielin O, Speiser DE. Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells. Int J Cancer. 2012 Jun 1;130(11):2607-17. doi: 10.1002/ijc.26297. Epub 2011 Aug 24. PMID 21796616